Testing Afimkibart for Moderate to Severe Crohn's Disease in Children
Tests afimkibart in children aged 2 to 17 with active Crohn's disease.
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- Bloemfontein and Pretoria, South AfricaSee the 2 sitesAlso in 7 other countries, 17 sites
- Trial code
- Registry title
- A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 100 people, planned
- Started
- 18 Aug 2026
- Expected to end
- 30 May 2031
- Type of study
- Interventional, 2 groups
- Treatments tested
- Afimkibart
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children aged 2 to 17 years with moderately to severely active Crohn's disease who did not do well on, or could not tolerate, earlier treatment.
- Age
- 2 to 17 years
- Sex
- Boys and girls can both join.
- Disease stage
- Moderately to severely active Crohn's disease, confirmed by a camera exam of the bowel (ileocolonoscopy). PCDAI score of 30 or more, and SES-CD score of 6 or more (4 or more if only the last part of the small bowel is affected).
- Earlier treatment
- Earlier treatment did not work well enough, stopped working, or was not tolerated. This covers at least one standard medicine (aminosalicylates, corticosteroids, immunosuppressants) or advanced therapy (anti-TNF, anti-interleukin, anti-integrin, JAK inhibitors).
Main reasons for not taking part
- Body weight under 10 kg (22 lb)
- A single-gene disorder causing inflammatory bowel disease in infancy
- 3 or more bowel operations that removed parts of the bowel
- Ulcerative colitis, fistula, abscess, or other types of colitis
- Narrowed bowel with symptoms, fulminant colitis, toxic megacolon, or primary sclerosing cholangitis
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Body weight >= 10 kilogram (kg)
- Active CD confirmed by endoscopy (ileocolonoscopy)
- Moderately to severely active CD, defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score >= 30, and Simple Endoscopic Score Crohn's Disease (SES-CD) >=6 (or >=4 for isolated ileal disease) confirmed through centrally-read ileocolonoscopy
- Inadequate response, loss of response, and/or intolerance to at least one of the following conventional therapies (aminosalicylates, corticosteroids and/or immunosuppressants) or advanced therapies (including anti-tumor necrosis factor, anti-interleukin, anti-integrin, or Janus Kinase (JAK) inhibitors)
Who cannot take part
- Monogenic disorder pertaining to infant onset Inflammatory Bowel Disease (IBD)
- History of >= 3 bowel resections: > 2 missing segments of the following five segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum
- Current diagnosis of ulcerative colitis (UC), abdominal/intraabdominal/perianal fistula and/or abscess, indeterminant colitis, IBD-unclassified, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, or active diverticular disease
- Symptomatic bowel strictures, fulminant colitis, or toxic megacolon
- Presence of abdominal or perianal abscess
- Current diagnosis or suspicion of primary sclerosing cholangitis
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 2 and 17 years old?
This trial is currently available in South Africa.
Also in 7 other countries, 17 sites
- IATROS InternationalBloemfontein, South AfricaTaking people
- Emmed ResearchPretoria, South AfricaTaking people
About the trial
What the trial wants to find out
This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).
The 2 groups in the trial
- Afimkibart Dose ATreatment being tested
Participants will receive Afimkibart intravenously (IV) followed by Afimkibart subcutaneous (SC) injection.
Treatment: Afimkibart
- Afimkibart Dose BTreatment being tested
Participants will receive Afimkibart IV followed by Afimkibart SC.
Treatment: Afimkibart
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2-17 Years With Moderately to Severely Active Crohn's Disease
- Plain-language title
- Testing Afimkibart for Moderate to Severe Crohn's Disease in ChildrenGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT07298421, who can take part
- Record updated
- 5 November 2026